PD153035 hydrochloride (ZM 252868, AG 1517) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM. PD153035 HCl shows a potent and selective inhibitory effect on tyrosine phosphorylation induced with EGF with IC50 of 15 nM and 14 nM in Swiss 3T3 fibroblast and A-431 human epidermoid carcinoma cells, respectively. PD153035 induces a dose-dependent growth inhibition in nasopharyngeal carcinoma (NPC) cells including NPC-TW01, NPC-TW04, and HONE1 cell lines with IC50 of 12.9 μM, 9.8 μM and 18.6μM, respectively. PD 153035 inhibits other purified tyrosine kinases only at micromolar or higher concentrations.
|Cell lines||A431, Difi, DU145, MDA-MB-468 and ME180|
|Preparation method||Seeding cells in sixwell plates. The next day, changing cells to medium containing 0.5% FBS for 18 hours, and then adding PD153035 at various concentrations to the cultures. After 72 hours of treatment, washing cells once with PBS, harvesting with 0.1% human trypsin-l mM EDTA in PBS, and counting with a Coulter counter. The CMK cells grow in suspension and, therefore, do not require trypsinization.|
|Incubation time||72 hours|
|Animal models||A431 cells are injected into the outbred nude mice|
|Formulation||PD153035 is dissolved in water.|
|Administration||Administered via i.p.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO <1 mg/mL
Water <1 mg/mL
Ethanol <1 mg/mL
Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.
Hsu CH, et al. Oncology. 2005;68(4-6):538-47. PMID: 16037687.
Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Bridges AJ, et al. J Med Chem. 1996 Jan 5;39(1):267-76. PMID: 8568816.
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.
Fry DW, et al. Science. 1994 Aug 19;265(5175):1093-5. PMID: 8066447.
|Related EGFR/HER2 Products|
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1，which can be used to treat non-small cell lung cancer.
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.